The optimal integration of new drugs into the treatment paradigm of HCC requires several key developments, including greater research into biomarkers that would help inform therapy choices, earlier treatment for patients diagnosed with HCC, and clinical trials that test combination strategies.
Immune-based approaches have revolutionized the treatment of acute lymphoblastic lymphoma, especially for patients unable to tolerate multiagent chemotherapy. Now, investigators are looking forward to seeing these agents move into frontline settings, perhaps leading to chemotherapy-free approaches.
Novel and emerging agents are creating exciting new options for patients with hormone receptor–positive metastatic breast cancer, resulting in the need to consider how best to introduce and sequence these agents into the treatment timeline.
A growing understanding about the underlying biology of myelofibrosis has helped improve the diagnosis and treatment of the disease during the past decade and is paving the way for further advancements.